Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, Novartis Expand Compound Profiling Deal

SAN FRANCISCO, Nov. 5 - Ciphergen Biosystems said today it expanded an agreement with Novartis to conduct compound profiling for the pharmaceutical company.


Ciphergen will use its SELDI ProteinChip systems and Biomarker Discovery Centers to evaluate samples for Novartis, according to the company.


Financial details of the agreement were not disclosed.


Ciphergen said the first project is a study with Novartis' oncology business unit to compare serum samples of responder and nonresponder patients given candidate drug treatment.


Click here for more information.


The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.